Sign in

    Suji Jeong

    former Equity Analyst at Jefferies

    Suji Jeong is a former Equity Analyst at Jefferies specializing in biotechnology and healthcare sectors, where she covered companies such as Stoke Therapeutics, Annexon, Savara, and Verona Pharma. During her tenure at Jefferies from 2018 to 2023, Jeong issued ratings with varied performance outcomes, including a recorded average return of approximately -11% and a success rate near 33% over at least three rated stocks. She holds a doctorate from Northwestern University and has since become Founding Partner at The SJR Group after leaving Jefferies. Jeong is recognized for her expertise in emerging healthcare trends and has hosted industry events focused on radiotherapeutics.

    Suji Jeong's questions to Savara (SVRA) leadership

    Suji Jeong's questions to Savara (SVRA) leadership • Q1 2020

    Question

    Suji Jeong from Jefferies asked whether the trial design for IMPALA 2 would be different for the European Union and if the company has had any discussions about the design with the European Medicines Agency (EMA).

    Answer

    Chief Medical Officer Badrul Chowdhury responded that conceptually, the trial design is unlikely to differ for the E.U. because the original IMPALA study design was consistent globally. He noted that the company will provide updates on interactions with other regulatory bodies once those discussions have occurred and the protocol is finalized.

    Ask Fintool Equity Research AI

    Suji Jeong's questions to Savara (SVRA) leadership • Q4 2019

    Question

    Suji Jeong from Jefferies LLC asked about the potential impact on statistical power from reducing the AeroVanc Phase 3 trial enrollment to approximately 140 patients. She also inquired about interactions with the EMA for the second IMPALA study and whether the number of deaths in the OPTIMA study was expected.

    Answer

    CEO Rob Neville stated that the reduced enrollment for the AeroVanc trial would have a minimal impact of a few percentage points on the study's power. Chief Medical Officer Badrul Chowdhury clarified that their priority is to agree on a study design with the FDA for IMPALA 2 before engaging with the EMA. He also confirmed that the three deaths in the OPTIMA study were reflective of the severe, advanced disease in that patient population.

    Ask Fintool Equity Research AI